AMPK (Adenosine Monophosphate Activated Protein Kinase) activating agent and application thereof in preparation of medicaments for treating diabetes mellitus and/or diabetic complication

A technology for diabetes and complications, applied in drug combination, drug delivery, urinary system diseases, etc.

Active Publication Date: 2013-03-13
SUZHOU UNIV
View PDF2 Cites 7 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

But so far, no research has shown that HSD and other 3H-1,2-dithiol-3-thione compounds have the pharmacologi...

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • AMPK (Adenosine Monophosphate Activated Protein Kinase) activating agent and application thereof in preparation of medicaments for treating diabetes mellitus and/or diabetic complication
  • AMPK (Adenosine Monophosphate Activated Protein Kinase) activating agent and application thereof in preparation of medicaments for treating diabetes mellitus and/or diabetic complication
  • AMPK (Adenosine Monophosphate Activated Protein Kinase) activating agent and application thereof in preparation of medicaments for treating diabetes mellitus and/or diabetic complication

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0079] The compound shown in embodiment 1 formula I is to the activation of macrophage cell AMPK

[0080] Take out the mouse macrophage cells from the liquid nitrogen tank and quickly place them in warm water at 37°C to shake gently to thaw, centrifuge at 1000 rpm for 3 minutes, discard the supernatant, and culture the cells in DMEM with a mass fraction of FBS of 10%. When the coverage rate of the cells in the culture dish reached 60%-70%, subculture was carried out. After the subcultured cell coverage reached 60%-70%, the cells were obtained by centrifugation at 1000 rpm for 3 min, stained with trypan blue, and counted under a microscope with a hemocytometer. Dilute the counted cells to a concentration of 150,000 / mL~200,000 / mL, and spread on a 96-well plate at a concentration of 15,000 / well to 20,000 / well.

[0081] Prepare a 3H-1,2-dithiocyclopentene-3-thione compound solution, weigh the compound shown in formula I, and dissolve it in DMSO so that the final concentration of ...

Embodiment 2

[0088] Example 2 The activating effect of the compound represented by formula I on macrophage AMPK under LPS-induced inflammation conditions

[0089] Take the mouse macrophage cells out of the liquid nitrogen tank and quickly place them in warm water at 37°C and shake gently to thaw, centrifuge at 1000 rpm for 3 minutes, discard the supernatant, and place the cells in DMEM medium with a mass fraction of FBS of 10%. Cultivate and subculture when the cell coverage in the culture dish reaches 60%-70%. After the subcultured cell coverage reached 60%-70%, the cells were obtained by centrifugation at 1000 rpm for 3 min, stained with trypan blue, and counted under a microscope with a hemocytometer. Dilute the counted cells to a concentration of 150,000 / mL~200,000 / mL, and spread on a 96-well plate at a concentration of 15,000 / well to 20,000 / well.

[0090] Prepare a 3H-1,2-dithiocyclopentene-3-thione compound solution, weigh the compound shown in formula I, and dissolve it in DMSO so ...

Embodiment 3

[0099] The activation effect of the compound shown in Example 3 formula I on human cell KEK293T AMPK

[0100] Take the KEK293T cells out of the liquid nitrogen tank and quickly place them in warm water at 37°C to shake gently to thaw, centrifuge at 1000 rpm for 3 minutes, discard the supernatant, and culture the cells in DMEM medium with a mass fraction of FBS of 10%. Subculture was carried out when the coverage rate in the petri dish reached 60%-70%. After the subcultured cell coverage reaches 60%-70%, centrifuge at 1000 rpm for 3 minutes to obtain the cells, stain with trypan blue, count 150,000 / mL~200,000 / mL under a microscope with a hemocytometer, and spread on a 96-well plate , 15,000 / hole to 20,000 / hole.

[0101] Prepare a 3H-1,2-dithiocyclopentene-3-thione compound solution, weigh the compound shown in formula I, and dissolve it in DMSO so that the final concentration of the solution is 50 mmol / L in terms of mass concentration.

[0102]

[0103] Formula I

[0104]...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention relates to the field of drugs, and in particular relates to an AMPK (Adenosine Monophosphate Activated Protein Kinase) activating agent and an application of the AMPK activating agent in preparation of medicaments for treating and/or preventing diabetes mellitus and/or diabetic complication. The invention provides an application of 3H-1, 2-benzodithiole-3-thioketone compound which has a structure shown in a formula I and serves as the AMPK activating agent, and an application of the 3H-1, 2-benzodithiole-3-thioketone compound in preparation of medicaments for treating and/or preventing diabetes mellitus and/or diabetic complication. The compound contains no biguanide group, so that no lactic acidosis occurs once the compound serves as the AMPK activating agent, and higher safety is ensured during the preparation of the medicaments for treating and/or preventing diabetes mellitus and/or diabetic complication.

Description

technical field [0001] The invention relates to the field of medicines, in particular to an AMPK activator and its application in the preparation of medicines for treating and / or preventing diabetes and / or diabetic complications. Background technique [0002] Diabetes is a disease process of multiple etiologies that affects 6% of the global population. It is estimated that by 2025, the number of patients will double to 300 million. The most important clinicopathological feature of diabetes is increased plasma glucose (blood sugar) concentration. Increased blood sugar concentration is the main cause of various clinical symptoms of diabetes. Uncontrolled hyperglycemia leads to many diabetic complications, such as increased risk of microvascular and macrovascular diseases, including nephropathy, neuropathy, retinopathy, hypertension, cerebral ischemia and coronary heart disease. Therefore, lowering blood sugar is the key to the treatment and prevention of diabetes and its co...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): A61K31/385A61K31/4436A61P3/10A61P9/12A61P9/00A61P3/04A61P25/00A61P9/10A61P13/12A61P15/00
CPCA61K9/48A61K9/08A61K9/02A61K9/20A61K31/4436A61K9/14A61K9/19A61K9/50A61K9/127A61K9/06A61K31/385A61P3/04A61P3/10A61P9/00A61P9/10A61P9/12A61P13/12A61P15/00A61P25/00
Inventor 程坚敖桂珍贾佳
Owner SUZHOU UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap